Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Current Investments (2017 - 2025)

Historic Cash & Current Investments for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $831.0 million.

  • Arcus Biosciences' Cash & Current Investments fell 2369.15% to $831.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $831.0 million, marking a year-over-year decrease of 2369.15%. This contributed to the annual value of $978.0 million for FY2024, which is 2885.38% up from last year.
  • Arcus Biosciences' Cash & Current Investments amounted to $831.0 million in Q3 2025, which was down 2369.15% from $911.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Cash & Current Investments registered a high of $1.2 billion during Q1 2022, and its lowest value of $499.0 million during Q4 2021.
  • Moreover, its 5-year median value for Cash & Current Investments was $954.0 million (2023), whereas its average is $906.8 million.
  • Examining YoY changes over the last 5 years, Arcus Biosciences' Cash & Current Investments showed a top increase of 42381.51% in 2021 and a maximum decrease of 3294.73% in 2021.
  • Over the past 5 years, Arcus Biosciences' Cash & Current Investments (Quarter) stood at $499.0 million in 2021, then soared by 102.2% to $1.0 billion in 2022, then decreased by 24.78% to $759.0 million in 2023, then rose by 28.85% to $978.0 million in 2024, then fell by 15.03% to $831.0 million in 2025.
  • Its last three reported values are $831.0 million in Q3 2025, $911.0 million for Q2 2025, and $997.0 million during Q1 2025.